In August 2003, Cytomatrix LLC was acquired by Singapore-based CordLife Pte Ltd. Cytomatrix researchs, develops and commercializes novel cell growth systems for hematopoietic (blood) stem cells. In decmber 2000, it was announced that privately-held Cytomatrix LLC and SELECT Therapeutics, Inc. (OTC:BB SLPU) had formed a joint venture named Cell Science Therapeutics to develop and commercialize novel biopharmaceutical products based on their proprietary technologies in cell culture, tissue engineering and immunotherapy. These applications target a number of clinical conditions in oncology, infectious diseases and certain autoimmune diseases. The joint venture's technology base encompasses all the assets of Cytomatrix in tissue engineering and design of regenerative T-cells as well as SELECT's vaccine program based on its Activate(tm) technology for presenting antigens to dendritic cells and its Veropulse(tm) tumor cell purging technology. All Cytromatrix employees are now associated to the joint venture currently funded at a $6 Million level.
